The Bull Case For Azenta (AZTA) Could Change Following Profitable Q4 and Upbeat Growth Guidance

Simply Wall St.11-30

Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2587769213?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/8211000-choice2-main-header/1585186947894","is_english":true,"pubTime":"2025-11-30 00:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2587769213","market":"hk","top_or_hot":-1,"title":"The Bull Case For Azenta (AZTA) Could Change Following Profitable Q4 and Upbeat Growth Guidance","media":"Simply Wall St.","content":"<div>\n<p>Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-azta/azenta/news/the-bull-case-for-azenta-azta-could-change-following-profita\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Azenta (AZTA) Could Change Following Profitable Q4 and Upbeat Growth Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Azenta (AZTA) Could Change Following Profitable Q4 and Upbeat Growth Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-30 00:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-azta/azenta/news/the-bull-case-for-azenta-azta-could-change-following-profita><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-azta/azenta/news/the-bull-case-for-azenta-azta-could-change-following-profita\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0031619046.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-azta/azenta/news/the-bull-case-for-azenta-azta-could-change-following-profita","article_id":"2587769213","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/8211000-choice2-main-header/1585186947894"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-azta/azenta/news/the-bull-case-for-azenta-azta-could-change-following-profita","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587769213","pubTimestamp":1764433123,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from the previous year.\nOne significant insight is Azenta’s transition from loss to profitability on both a net income and earnings per share basis, accompanied by positive guidance for continued organic revenue growth into fiscal year 2026.\nWe’ll explore how Azenta’s return to profitability and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4147":"半导体设备","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4121":"生命科学工具和服务","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","AZTA":"Azenta","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC"},"translate_title":"在第四季度盈利和乐观的增长指引之后，Azenta(AZTA)的牛市可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZTA":1.5},"content_text":"Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from the previous year. One significant insight is Azenta’s transition from loss to profitability on both a net income and earnings per share basis, accompanied by positive guidance for continued organic revenue growth into fiscal year 2026. We’ll explore how Azenta’s return to profitability and growth forecast could reshape its investment narrative and future outlook. These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AdvertisementAzenta Investment Narrative Recap To be a shareholder in Azenta today, you would need to believe in the company’s ability to sustain revenue growth through the ongoing expansion of life sciences automation and outsourcing. The company's recent return to profitability and its outlook for organic revenue growth may strengthen the case for continued momentum, but the short-term catalyst remains the pace of recovery in higher-margin capital equipment sales, while the biggest risk continues to be delays from customer budget pressures, which remain largely unchanged after the latest earnings.\n  Among recent announcements, the fiscal year 2026 revenue growth guidance of 3% to 5% stands out as closely tied to current performance. This communicates management’s focus on incremental top-line growth in the face of sector headwinds and indicates that forecasts of recurring service revenues remain an important watchpoint for short-term results.\n  In contrast, investors should also be aware that the pace of order recovery for core capital equipment, particularly if customer budget constraints persist, may…\n Read the full narrative on Azenta (it's free!)Azenta's outlook suggests $684.6 million in revenue and $34.5 million in earnings by 2028. This is based on a forecast revenue decline of 0.8% per year and a $202 million increase in earnings from the current level of -$167.5 million.Uncover how Azenta's forecasts yield a $39.83 fair value, a 12% upside to its current price.Exploring Other PerspectivesAZTA Earnings & Revenue Growth as at Nov 2025  Fair value estimates from two Simply Wall St Community members range from US$36.28 to US$39.83, reflecting different views on Azenta’s earnings and revenue outlook. While market participants see varied upside, recent guidance on organic growth remains central to the company’s forward performance, making it important to compare multiple perspectives.\nExplore 2 other fair value estimates on Azenta - why the stock might be worth as much as 12% more than the current price!Build Your Own Azenta NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Azenta research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Azenta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Azenta's overall financial health at a glance.Curious About Other Options?Opportunities like this don't last. These are today's most promising picks. Check them out now:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2587769213","isCrawlerRequest":true}